Investigating resistance to anti-estrogen therapy in aggressive breast cancer.
Official title: WNT pathway-driven anti-estrogen therapy resistance in breast cancer
Funded at Thomas Jefferson University · NIH-11083025 · Data updated 2026-11-12
This study is looking at a tough type of breast cancer called lumino-basal breast cancer, especially in women under 50, to find out why some treatments that block estrogen don’t work well, with the hope of discovering better ways to help those affected.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | December 1, 2022 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $549,696 |
| NIH project number | 5R01CA267549-03 |
| Project ID | NIH-11083025 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are young women under 50 diagnosed with estrogen receptor-positive lumino-basal breast cancer.
✕Less likely to help
Patients with other types of breast cancer or those who are not estrogen receptor-positive may not benefit from this research.
What this research studies
This research focuses on a specific type of aggressive breast cancer known as lumino-basal breast cancer (LBBC), which is characterized by a mix of estrogen receptor-positive and negative cells. The study aims to understand how these cancers resist anti-estrogen therapies, particularly in younger women under 50. By examining the role of certain hormones and signaling pathways, the research seeks to identify mechanisms that contribute to therapy resistance. Patients may benefit from insights that could lead to more effective treatment strategies tailored to this aggressive cancer subtype.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with therapy-resistant breast cancer.
How similar studies have gone: Previous research has shown promising results in understanding therapy resistance in breast cancer, but this specific approach targeting LBBC is relatively novel.
Where this research is happening
-
Thomas Jefferson University
Philadelphia, United States Active
Researchers
- Principal investigator: Rui, Hallgeir — Thomas Jefferson University
- Study coordinator: Rui, Hallgeir
Related research
Other NIH-funded projects on the same topics.
-
Improving Breast Cancer Guideline Adherence in Nigeria
Aimed at helping doctors in Nigeria follow international guideline-based breast cancer care to improve outcomes for women with breast cancer.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Translational breast cancer research to improve treatment options
A comprehensive program at Baylor College of Medicine is focusing on breast cancer; researchers will advance targeted therapies and biomarkers to help patients with aggressive or hard-to-treat forms.
-
Cancer Pain Management for Asian American Breast Cancer Survivors with Depressive Symptoms
A technology-based program helps Asian American breast cancer survivors with depressive symptoms manage chronic pain more effectively from home using a web app and mobile tools.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Gut bacteria and metabolites linked to breast density and cancer risk
A small, patient-friendly study will explore whether gut bacteria and their byproducts are connected to high breast density, which can raise cancer risk and make screening less accurate.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.